The American Cancer Society has announced the inclusion of a new blood test named 'Shield' among the screening options for detecting colon and rectal cancer. This decision is part of the Society's efforts to expand available screening options and reduce barriers to early diagnosis, especially for individuals who avoid colonoscopies or stool tests.
The 'Shield' test was developed by Guardant Health and received approval from the Food and Drug Administration in 2024. This innovative test relies on detecting tumor-derived genetic material present in the bloodstream, making it a groundbreaking option for colon and rectal cancer detection.
Event Details
In a press statement, Dr. Robert Smith, Vice President of the American Cancer Society, emphasized the need for increased focus on colon and rectal cancer, as it is a largely preventable disease. He noted that the inclusion of the 'Shield' test reflects advancements in disease detection technologies and represents a significant shift in public health strategy.
The updated guidelines also include at-home stool tests, such as the 'Cologuard' test produced by Exact Sciences and the 'Cologuard' test developed by Genoscape. These tests focus on identifying subtle blood and molecular indicators of cancer and are characterized by high sensitivity in detecting colon and rectal cancer.
Background & Context
Colon and rectal cancer is among the most common types of cancer worldwide and poses a significant health threat. According to statistics, early detection of the disease can increase treatment and recovery chances. Therefore, the development of new tests like 'Shield' represents an important step in improving patient outcomes.
The American Cancer Society aims, through these recommendations, to encourage more individuals to undergo necessary screenings, which could contribute to reducing incidence and mortality rates associated with this disease.
Impact & Consequences
The inclusion of the 'Shield' test in the recommendations is a positive step toward improving access to health screenings. This test could encourage individuals who have been avoiding traditional screenings to take a step toward early detection.
However, it is important to use the blood test as a secondary option, as stool tests remain more sensitive in detecting health changes that precede cancer. Therefore, the Society recommends undergoing a colonoscopy if the results are positive.
Regional Significance
In the Arab region, colon and rectal cancer is a disease that requires increased awareness and early detection. The introduction of new options like the 'Shield' test may contribute to improving early detection rates, leading to better treatment outcomes.
Arab communities need to enhance awareness programs about the importance of early screening, especially in light of rising incidence rates. These new tests could serve as effective tools in achieving that goal.